Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Core Viewpoint - Plus Therapeutics, Inc. has announced a public offering of 39,473,684 units at a price of $0.38 per unit, aiming to raise approximately $15 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - Each unit consists of one share of common stock and one warrant, with each warrant exercisable at $0.38 per share and expiring five years from issuance [1]. - The underwriter has a 30-day option to purchase up to an additional 5,921,052 shares and/or warrants to cover over-allotments [1]. Group 2: Financial and Regulatory Information - The offering is expected to close on January 15, 2026, subject to customary closing conditions [2]. - A registration statement related to the securities was filed with the SEC on January 9, 2026, and declared effective on January 13, 2026 [3]. Group 3: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging CNS cancers, with a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [5]. - The company has established a supply chain through strategic partnerships to support the development and potential commercialization of its products [5]. Group 4: Subsidiary Information - CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, develops proprietary tests like CNSide® to identify tumor cells in the CNS for patients with carcinomas and melanomas [6].